Back to Journals » Journal of Inflammation Research » Volume 13

Mesenchymal Stem Cells Anti-Inflammatory Activity in Rats: Proinflammatory Cytokines

Authors Petryk N, Shevchenko O

Received 14 April 2020

Accepted for publication 27 June 2020

Published 7 July 2020 Volume 2020:13 Pages 293—301

DOI https://doi.org/10.2147/JIR.S256932

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Ning Quan


Video abstract presented by Nataliia Petryk.

Views: 210

Nataliia Petryk, Oleksandr Shevchenko

Department of Pathology, Kharkiv National Medical University, Kharkiv, Ukraine

Correspondence: Nataliia Petryk
Department of Pathology, Kharkiv National Medical University, Kharkiv, Ukraine
Email perfectgynecologist@gmail.com

Introduction: Many widespread intractable diseases are caused or supported by chronic inflammation. Such conditions include the 2nd type of diabetes mellitus, atherosclerosis, neurodegenerative diseases, chronic inflammatory diseases of the connective tissue - ankylosing spondylitis, rheumatoid arthritis, autoimmune myositis, etc. Therefore, the search for targeted treatment of these illnesses is extremely in high demand. Immunomodulatory activity of mesenchymal stem cells is one of their remarkable properties. Several biomarkers (cytokines and nonspecific proteins) are known to be associated with chronic inflammation.
Methods: Our study aimed to investigate the serum levels of tumor necrosis factor-alpha, interleukin 6 and C-reactive protein in carrageenan myositis in rats, because there is more and more evidence of the significance of these markers in the course and resolution of the diseases mentioned above. For the first time in our experiment, it was shown and evaluated using analysis of variance, how MSCs influence the indicators of proinflammatory cytokines on the model of carrageenan myositis. The levels of α-TNF, IL-6 and CRP in the plasma of rats were studied in groups with chronic carrageenan inflammation and chronic inflammation with local injection of MSCs into the affected area.
Results: Our study proved the effectiveness of MSCs by showing a significant decrease in the levels of inflammatory mediators in the plasma of the studied animals.
Discussion and Conclusions: Thus, the administration of MSCs is a promising tool in the pathogenic treatment of chronic inflammation and concomitant conditions.

Keywords: chronic inflammation, mesenchymal stem cells, carrageenan, tumor necrosis factor-alpha, interleukin-6, C-reactive protein

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]